NVCR

NovoCure Limited

NovoCure Ltd is a medical systems developer in the United States. Its primary product is the TTFields delivery system, which is a low-intensity therapy to combat acute tumors.

NovoCure Limited (NVCR) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Momentum (C).

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
B
Factor Score 3.3 / 5.0
Momentum
C
Factor Score 2.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -16.1
EV / EBITDA -11.0
Rev Growth YoY 15.7%
Gross Margin 77.3%
Price Return 3M -30.9%
Price Return 12M -1.2%
Catalyst Signal 0.00
Market Cap $1.4B
TTM Revenue $725.4M
Price / Sales 1.9
ROE -35.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (3.0) C+ (2.5) B (3.3) C (2.2) C+ (2.6) C+ (2.7)
2026-11-06 B- (3.0) C+ (2.5) B (3.3) C+ (2.5) C+ (2.7) C+ (2.8)
2026-10-30 B- (3.0) C+ (2.5) B (3.4) C+ (2.8) C+ (2.7) B- (2.9)
2026-10-23 B- (3.0) C+ (2.5) B (3.4) B- (2.9) C+ (2.6) B- (2.9)
2026-10-16 B- (3.0) C+ (2.5) B (3.4) B- (3.0) C+ (2.6) B- (2.9)
Page 1 of 5